NZ560990A - Compositions for oral transmucosal delivery of metformin - Google Patents

Compositions for oral transmucosal delivery of metformin Download PDF

Info

Publication number
NZ560990A
NZ560990A NZ560990A NZ56099006A NZ560990A NZ 560990 A NZ560990 A NZ 560990A NZ 560990 A NZ560990 A NZ 560990A NZ 56099006 A NZ56099006 A NZ 56099006A NZ 560990 A NZ560990 A NZ 560990A
Authority
NZ
New Zealand
Prior art keywords
composition
metformin
pharmaceutically acceptable
subject
medicament
Prior art date
Application number
NZ560990A
Other languages
English (en)
Inventor
Anna E Gluskin
Muhammad Waseem Tahir Qazi
Original Assignee
Generex Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generex Pharm Inc filed Critical Generex Pharm Inc
Publication of NZ560990A publication Critical patent/NZ560990A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A61K9/0058Chewing gums
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/155Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
NZ560990A 2005-03-30 2006-03-30 Compositions for oral transmucosal delivery of metformin NZ560990A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US66647505P 2005-03-30 2005-03-30
PCT/CA2006/000472 WO2006102752A1 (en) 2005-03-30 2006-03-30 Compositions for oral transmucosal delivery of metformin

Publications (1)

Publication Number Publication Date
NZ560990A true NZ560990A (en) 2009-02-28

Family

ID=37052910

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ560990A NZ560990A (en) 2005-03-30 2006-03-30 Compositions for oral transmucosal delivery of metformin

Country Status (16)

Country Link
US (1) US20090069437A1 (enExample)
EP (1) EP1863465A4 (enExample)
JP (1) JP2008534523A (enExample)
AR (1) AR052960A1 (enExample)
AU (1) AU2006228949A1 (enExample)
BR (1) BRPI0611555A2 (enExample)
CA (1) CA2603450A1 (enExample)
CR (1) CR9363A (enExample)
IL (1) IL185931A0 (enExample)
MX (1) MX2007012047A (enExample)
NZ (1) NZ560990A (enExample)
PE (1) PE20061245A1 (enExample)
RU (2) RU2409357C2 (enExample)
UY (1) UY29445A1 (enExample)
WO (1) WO2006102752A1 (enExample)
ZA (1) ZA200708834B (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080025A1 (en) * 2007-12-20 2009-07-02 Fertin Pharma A/S Compressed chewing gum comprising metformin
WO2009090210A2 (en) * 2008-01-16 2009-07-23 Janssen Pharmaceutica Nv Combination of metformin and an mtp inhibitor
CA2638240C (en) * 2008-08-29 2010-02-02 Alexander Macgregor Method of treating dysglycemia and glucose excursions
CN102316872B (zh) * 2008-11-26 2016-12-21 萨蒂奥根制药公司 治疗肥胖症和糖尿病的胆汁酸再循环抑制剂
EP2445494A4 (en) * 2009-06-24 2012-12-12 Univ Koebenhavn TREATMENT OF INSULIN RESISTANCE AND OBESITY BY STIMULATING GLP-1 RELEASE
WO2011051974A1 (en) * 2009-10-29 2011-05-05 Nutracryst Therapeutics Private Limited Metformin and a-amino acids
EP3593802A3 (en) 2010-05-26 2020-03-25 Satiogen Pharmaceuticals, Inc. Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions
EA030839B1 (ru) 2011-10-28 2018-10-31 ЛУМЕНА ФАРМАСЬЮТИКАЛС ЭлЭлСи Ингибиторы рециклинга желчных кислот при лечении холестатических заболеваний печени у детей
WO2013063526A1 (en) 2011-10-28 2013-05-02 Lumena Pharmaceuticals, Inc. Bile acid recycling inhibitors for treatment of hypercholemia and cholestatic liver disease
EP3696281A1 (en) * 2019-02-13 2020-08-19 Johann Wolfgang Goethe-Universität Frankfurt am Main Arginase as biomarker and drug target for pcos
WO2020227344A1 (en) * 2019-05-06 2020-11-12 The Regents Of The University Of California Chloride intracellular channel 1 for regulation of food intake

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK161428C (da) * 1985-05-10 1991-12-16 Fertin Lab As Fast, oralt cariesmodvirkende middel
DK365389D0 (da) * 1989-07-24 1989-07-24 Fertin Lab As Antifungalt tyggegummipraeparat
US20030095925A1 (en) * 1997-10-01 2003-05-22 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating metabolic disorders
FR2775188B1 (fr) * 1998-02-23 2001-03-09 Lipha Forme galenique a liberation immediate ou liberation prolongee administrable par voie orale comprenant un agent promoteur d'absorption et utilisation de cet agent promoteur d'absorption
US6099859A (en) * 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
WO1999055320A1 (en) * 1998-04-29 1999-11-04 Sumitomo Pharmaceuticals Co., Ltd. Oral formulation comprising biguanide and an organic acid
DK0974356T3 (da) * 1998-07-15 2003-10-27 Merck Sante Sas Tabletter omfattende en kombination af metformin og glibenclamid
US6099862A (en) * 1998-08-31 2000-08-08 Andrx Corporation Oral dosage form for the controlled release of a biguanide and sulfonylurea
US6344222B1 (en) * 1998-09-03 2002-02-05 Jsr Llc Medicated chewing gum delivery system for nicotine
US6312665B1 (en) * 1998-12-21 2001-11-06 Generex Pharmaceuticals Incorporated Aerosol formulations for buccal and pulmonary application
US6432383B1 (en) * 2000-03-30 2002-08-13 Generex Pharmaceuticals Incorporated Method for administering insulin
BR0115390A (pt) * 2000-11-03 2004-02-25 Andrx Corp Formulações para liberação controlada de metformina, liberação controlada da forma farmacêutica oral, método de diminuição dos nìveis de glicose sanguìnea, uso da forma farmacêutica
ITMI20011337A1 (it) * 2001-06-26 2002-12-26 Farmatron Ltd Composizioni farmaceutiche orali a rilascio modificato del principio attivo
ITFI20010230A1 (it) * 2001-11-29 2003-05-29 Menarini Int Operations Lu Sa Composizioni farmaceutiche per il trattamento del diabete mellito di tipo ii
KR20100137023A (ko) * 2002-09-20 2010-12-29 안드렉스 랩스 엘엘씨 약제학적 정제
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
WO2005041926A1 (en) * 2003-10-31 2005-05-12 Alza Corporation Compositions and dosage forms for enhanced absorption of 3-amino-n-butyl-phosphinic acid

Also Published As

Publication number Publication date
RU2007139886A (ru) 2009-05-10
JP2008534523A (ja) 2008-08-28
RU2010139163A (ru) 2012-03-27
US20090069437A1 (en) 2009-03-12
AU2006228949A1 (en) 2006-10-05
BRPI0611555A2 (pt) 2010-09-21
EP1863465A1 (en) 2007-12-12
ZA200708834B (en) 2008-11-26
WO2006102752A1 (en) 2006-10-05
RU2409357C2 (ru) 2011-01-20
UY29445A1 (es) 2006-10-02
MX2007012047A (es) 2007-12-12
CR9363A (es) 2008-02-12
IL185931A0 (en) 2008-02-09
EP1863465A4 (en) 2010-12-15
AR052960A1 (es) 2007-04-11
PE20061245A1 (es) 2007-01-06
CA2603450A1 (en) 2006-10-05

Similar Documents

Publication Publication Date Title
JP5179757B2 (ja) 口腔粘膜を介して催眠剤をデリバリーするための組成物及びその使用方法
US6375982B1 (en) Rapid-melt semi-solid compositions, methods of making same and method of using same
AU2018217251A1 (en) Buccal and/or sublingual therapeutic formulation
SG174785A1 (en) Methods to administer solid dosage forms of ethinyl estradiol and prodrugs thereof with improved bioavailabilty
WO2009080023A1 (en) Compressed chewing gum comprising peptide
US20180078534A1 (en) Compositions and methods for treating middle-of-the-night insomnia
US20090069437A1 (en) Compositions for Oral Transmucosal Delivery of Metformin
US20100249178A1 (en) Compositions and methods for treating middle-of-the-night insomnia
US20110274728A1 (en) Compositions and Methods for Alleviating Hyposalivation and for Providing Oral Comfort
JPH05501854A (ja) 親油性薬剤の非侵襲性用量対効果式投与のための方法及び組成物
Ughade et al. Medicated chewing gum: Modern approach to mucosal drug delivery
US20190099368A1 (en) Chewable dosage forms containing sitagliptin and metformin
US20030108605A1 (en) Mineral supplement
RU2389493C2 (ru) Композиция и способ для повышения уровня глюкозы в крови
Makwana et al. Chewing gum: A modern approach to oral mucosal drug delivery
US11096890B2 (en) Chewable dosage forms containing sitagliptin and metformin
MXPA06009296A (es) Composiciones para suministro de agentes hipnoticos a traves de la mucosa oral y sus metodos de uso.
US20080085331A1 (en) Composition and method for raising blood glucose level
Lakkis Encapsulation and controlled release applications in confectionery and oral care products
Singh et al. A REVIEW ON DIFFERENT FORMULATIONS OF BACLOFEN FOR SPASTICITY
CA2562821A1 (en) Composition and method for raising blood glucose level
JP2002121146A (ja) 歯周病予防用製剤
Thombre et al. Available online through www. jpronline. info
JUNO et al. PHARMACEUTICAL SCIENCES
HK1030749B (en) Oral liquid formulations of benzoxazinones hiv reverse transcriptase inhibitors

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)
LAPS Patent lapsed